Lycopus (Herb/Suppl)

Brand and Other Names:bugleweed, gypsywort, more...Virginia bugleweed, water horehound, wolfstrappkraut
  • Print

Suggested Dosing

0.2-2 g/day whole herb PO

Commerically available preparation: 2 tablet (40 mg) PO qD

Next:

Suggested Uses

Hyperthyroidism, PMS, breast pain, nervousness, insomnia; and bleeding, especially nosebleeds and heavy bleeding during menses

Efficacy

There is insufficient reliable information available about the effectiveness

Previous
Next:

Interactions

Interaction Checker

and Lycopus

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (2)

              • levothyroxine

                lycopus decreases effects of levothyroxine by pharmacodynamic antagonism. Contraindicated. Lycopus blocks peripheral conversion of T4 to T3.

              • thyroid desiccated

                lycopus decreases effects of thyroid desiccated by pharmacodynamic antagonism. Contraindicated. Lycopus blocks peripheral conversion of T4 to T3.

              Monitor Closely (3)

              • iodine (radioactive)

                lycopus increases effects of iodine (radioactive) by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3.

              • methimazole

                lycopus increases effects of methimazole by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3.

              • propylthiouracil

                lycopus increases effects of propylthiouracil by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3.

              Minor (23)

              • acarbose

                lycopus increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • chlorpropamide

                lycopus increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • glimepiride

                lycopus increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • glipizide

                lycopus increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • glyburide

                lycopus increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • insulin aspart

                lycopus increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • insulin detemir

                lycopus increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • insulin glargine

                lycopus increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • insulin glulisine

                lycopus increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • insulin lispro

                lycopus increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • insulin NPH

                lycopus increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • insulin regular human

                lycopus increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • metformin

                lycopus increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • miglitol

                lycopus increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • nateglinide

                lycopus increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • pioglitazone

                lycopus increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • repaglinide

                lycopus increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • rosiglitazone

                lycopus increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • saxagliptin

                lycopus increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • sitagliptin

                lycopus increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • tolazamide

                lycopus increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • tolbutamide

                lycopus increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              • vildagliptin

                lycopus increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

              Previous
              Next:

              Adverse Effects

              None in regular doses

              Previous
              Next:

              Warnings

              Contraindications

              Pregnancy, lactation

              Hypothyroidism

              Cautions

              May cause hypoglycemia

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy Category: avoid

              Lactation: avoid

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Metabolism: N/A

              Excretion: N/A

              Mechanism of Action

              Contains organic acids, eg, lithospermic acid that decrease levels of several hormones, particularly TSH & thyroxine (T4)

              Also inhibits binding of antibodies to thyroid that cause Graves disease

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.